01801 Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

0 Analyst Rating

Wall Street analysts forecast 01801 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

JPMorgan

Overweight

downgrade

$166 -> $149

2025-12-19

Reason

JPMorgan

Price Target

$166 -> $149

2025-12-19

downgrade

Overweight

Reason

The analyst rating from JPMorgan is based on the belief that the fundamentals of the Chinese healthcare sector remain unchanged despite recent market weakness. The report suggests that the pullback in the sector, attributed to national medical insurance drug list price negotiations and profit-taking, presents a favorable entry point for investments looking towards 2026. JPMorgan specifically favors biotechnology and CXO stocks, highlighting top picks and maintaining Overweight ratings for several companies, indicating a positive outlook for their performance.

JPMorgan

maintain

$110

2025-12-09

Reason

JPMorgan

Price Target

$110

2025-12-09

maintain

Reason

The analyst rating from JPMorgan for INNOVENT BIO is "Overweight." The reasoning behind this rating includes: 1. Market Potential: The weight loss drug market in China is considered vast, providing significant opportunities for multiple blockbuster drugs, which supports optimism about INNOVENT BIO's prospects. 2. Product Pipeline: JPMorgan is optimistic about INNOVENT BIO's product pipeline, which covers various fields such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology. 3. Flexible Pricing Strategy: Despite concerns regarding competition from Eli Lilly's tirzepatide, JPMorgan believes that INNOVENT BIO's mazdutide can adopt a flexible pricing strategy in response to market changes. 4. Future Growth Forecast: The broker forecasts that by 2027, INNOVENT BIO will have more than ten products on the market, with projected sales reaching RMB17 billion. Overall, these factors contribute to a positive outlook for the company, justifying the "Overweight" rating.

CCBI

Outperform

maintain

$125 -> $128

2025-11-07

Reason

CCBI

Price Target

$125 -> $128

2025-11-07

maintain

Outperform

Reason

The analyst rating for INNOVENT BIO was influenced by several positive factors highlighted in the article. The company's total product revenue for 3Q25 grew by over 40% year-over-year, exceeding expectations and surpassing the broker's full-year growth forecast of 37%. Additionally, the revenue increased by 22% quarter-over-quarter, which was a faster pace compared to the previous year. CCBI, the research firm, views INNOVENT BIO as a leader in China's biologics market for treating challenging chronic and fatal diseases, prompting them to raise their revenue forecasts for the company for 2025-27. They also increased the adjusted earnings forecasts for the same period. As a result of these strong performance indicators and positive outlook, CCBI raised the target price for INNOVENT BIO from HKD 125 to HKD 128 while maintaining an "Outperform" rating.

CMBI

Buy

maintain

2025-10-24

Reason

CMBI

Price Target

2025-10-24

maintain

Buy

Reason

The analyst rating for INNOVENT BIO was maintained at "Buy" due to the announcement of a global strategic partnership with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments that enhance the company's financial outlook. CMBI expressed optimism about the global development of key oncology assets IBI363 and IBI343, leading to an increase in the target price from $109.48 to $110.62 based on the discounted cash flow (DCF) method.

JPMorgan

maintain

$114 -> $110

2025-10-23

Reason

JPMorgan

Price Target

$114 -> $110

2025-10-23

maintain

Reason

The analyst rating for INNOVENT BIO was reaffirmed as "Overweight" by JPMorgan due to the company's recent global collaboration agreement with Takeda Pharmaceutical, which includes a significant upfront payment and potential milestone payments. This agreement is seen as a strategic move that strengthens INNOVENT BIO's market position in the US and enhances its capabilities for independent global clinical development and commercialization. Despite trimming the target price from $114 to $110, the overall outlook remains positive, leading to the continued endorsement as a top pick in China's biopharma sector.

CLSA

upgrade

2025-10-23

Reason

CLSA

Price Target

2025-10-23

upgrade

Reason

The analyst rating for INNOVENT BIO was influenced by the positive outlook stemming from its global strategic collaboration with Takeda Pharmaceutical. CLSA viewed this partnership favorably for INNOVENT BIO's global expansion and product development, particularly in advancing the core project IBI363. As a result of this collaboration, CLSA raised its sales and net profit forecasts significantly for FY26 and made a slight increase for FY27. Consequently, the target price for INNOVENT BIO was increased, and the Outperform rating was maintained.

Valuation Metrics

The current forward P/E ratio for INNOVENT BIO (01801.HK) is 50.91, compared to its 5-year average forward P/E of 77.20. For a more detailed relative valuation and DCF analysis to assess INNOVENT BIO 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

77.20

Current PE

50.91

Overvalued PE

527.22

Undervalued PE

-372.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-40.99

Current EV/EBITDA

63.34

Overvalued EV/EBITDA

125.56

Undervalued EV/EBITDA

-207.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

10.00

Current PS

8.00

Overvalued PS

15.42

Undervalued PS

4.59

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

01801 News & Events

Events Timeline

No data

News

4.5

04:12 AMaastocks

<Midday Update> HSI Falls 272 Points; HSTI Declines by 96 Points; BABA Drops More Than 4%; CHINAHONGQIAO, CHINA LIFE, NANSHAN AL INTL, ND PAPER, CMOC Reach New Peaks

4.5

01-05aastocks

<Midday Update> HSI Ends Midday at 26,316, Decreasing by 21 Points; HSTI Ends Midday at 5,726, Dropping 10 Points; PING AN Rises Over 3%; PING AN, CHINA LIFE, NCI, CHALCO, CIMC ENRIC Reach New Peaks

4.0

01-05aastocks

Daiwa Selects INNOVENT BIO (01801.HK) and HENGRUI PHARMA (600276.SH) as Top Picks, Raises Target Price to HKD112

People Also Watch

Frequently Asked Questions

What is INNOVENT BIO (01801) stock price today?

The current price of 01801 is 89.05 USD — it has increased 5.38 % in the last trading day.

What is INNOVENT BIO (01801)'s business?

What is the price predicton of 01801 Stock?

Wall Street analysts forecast 01801 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is INNOVENT BIO (01801)'s revenue for the last quarter?

INNOVENT BIO revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is INNOVENT BIO (01801)'s earnings per share (EPS) for the last quarter?

INNOVENT BIO. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for INNOVENT BIO (01801)'s fundamentals?

The market is revising No Change the revenue expectations for 01801 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.

How many employees does INNOVENT BIO (01801). have?

INNOVENT BIO (01801) has 0 emplpoyees as of January 07 2026.

What is INNOVENT BIO (01801) market cap?

Today 01801 has the market capitalization of 0.00 USD.

01801

Overview

Forecast

Valuation

Earnings

01801

Overview

Forecast

Valuation

Earnings

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

01801 News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is INNOVENT BIO (01801) stock price today?

What is INNOVENT BIO (01801)'s business?

What is the price predicton of 01801 Stock?

What is INNOVENT BIO (01801)'s revenue for the last quarter?

What is INNOVENT BIO (01801)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for INNOVENT BIO (01801)'s fundamentals?

How many employees does INNOVENT BIO (01801). have?

What is INNOVENT BIO (01801) market cap?